

Carina Blomström-Lundqvist

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8524754/publications.pdf>

Version: 2024-02-01

115
papers

11,712
citations

136950

32
h-index

30087

103
g-index

118
all docs

118
docs citations

118
times ranked

10635
citing authors

#	ARTICLE	IF	CITATIONS
1	Lead fixation mechanism impacts outcome of transvenous lead extraction: data from the European Lead Extraction ConTRolled Registry. <i>Europace</i> , 2022, 24, 817-827.	1.7	9
2	European Society of Cardiology Quality Indicators for the care and outcomes of cardiac pacing: developed by the Working Group for Cardiac Pacing Quality Indicators in collaboration with the European Heart Rhythm Association of the European Society of Cardiology. <i>Europace</i> , 2022, 24, 165-172.	1.7	20
3	Recent-onset atrial fibrillation: a study exploring the elements of Virchow's triad after cardioversion. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2022, 64, 49-58.	1.3	2
4	Clinical utility and prognostic implications of the novel 4S-AF scheme to characterize and evaluate patients with atrial fibrillation: a report from ESC-EHRA EORP-AF Long-Term General Registry. <i>Europace</i> , 2022, 24, 721-728.	1.7	12
5	Atrial fibrillation ablation in heart failure: Findings from the ESC-EHRA EORP Atrial Fibrillation Ablation long-term (AFA LT) registry. <i>International Journal of Cardiology</i> , 2022, 346, 19-26.	1.7	2
6	Reflections on the usefulness of today's atrial fibrillation ablation procedure endpoints and patient-reported outcomes. <i>Europace</i> , 2022, 24, ii29-ii43.	1.7	6
7	Impact of renal impairment on atrial fibrillation: ESC-EHRA EORP-AF Long-Term General Registry. <i>European Journal of Clinical Investigation</i> , 2022, 52, e13745.	3.4	10
8	Repolarisation abnormalities unmasked with a 252-lead BSM system in patients with ARVC and healthy Gene Carriers. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2022, , .	1.2	3
9	Antibiotic-Eluting Envelopes for the Prevention of Cardiac Implantable Electronic Device Infections: Rationale, Efficacy, and Cost-Effectiveness. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 855233.	2.4	3
10	AIM-AF: A Physician Survey in the United States and Europe. <i>Journal of the American Heart Association</i> , 2022, 11, e023838.	3.7	10
11	Identifying risk of adverse outcomes in COVID-19 patients via artificial intelligence-powered analysis of 12-lead intake electrocardiogram. <i>Cardiovascular Digital Health Journal</i> , 2022, 3, 62-74.	1.3	5
12	Machine learning-derived major adverse event prediction of patients undergoing transvenous lead extraction: Using the ESC EHRA EORP European lead extraction ConTRolled ELECTRa registry. <i>Heart Rhythm</i> , 2022, 19, 885-893.	0.7	5
13	Impact of diabetes on the management and outcomes in atrial fibrillation: an analysis from the ESC-EHRA EORP-AF Long-Term General Registry. <i>European Journal of Internal Medicine</i> , 2022, 103, 41-49.	2.2	5
14	Short P-Wave Duration Is Associated with Incident Atrial Fibrillation. <i>International Heart Journal</i> , 2022, 63, 700-707.	1.0	5
15	Adenosine usage during AF ablation in Europe and selected long-term findings from the ESC-EHRA EORP Atrial Fibrillation Ablation Long-Term registry. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2021, 60, 395-406.	1.3	1
16	Impact of centre volume on atrial fibrillation ablation outcomes in Europe: a report from the ESC EHRA EORP Atrial Fibrillation Ablation Long-Term (AFA LT) Registry. <i>Europace</i> , 2021, 23, 49-58.	1.7	6
17	2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). <i>European Heart Journal</i> , 2021, 42, 373-498.	2.2	5,583
18	The 4S-AF Scheme (Stroke Risk; Symptoms; Severity of Burden; Substrate): A Novel Approach to In-Depth Characterization (Rather than Classification) of Atrial Fibrillation. <i>Thrombosis and Haemostasis</i> , 2021, 121, 270-278.	3.4	118

#	ARTICLE	IF	CITATIONS
19	Risk stratification of patients undergoing transvenous lead extraction with the ELECTRa Registry Outcome Score (EROS): an ESC EHRA EORP European lead extraction ConTRolled ELECTRa registry analysis. <i>Europace</i> , 2021, 23, 1462-1471.	1.7	38
20	Redefining the Standard for Atrial Fibrillation: A Patient-centric Report. <i>European Cardiology Review</i> , 2021, 16, 1-6.	2.2	0
21	The effect of centre volume and procedure location on major complications and mortality from transvenous lead extraction: an ESC EHRA EORP European Lead Extraction ConTRolled ELECTRa Registry subanalysisâ€”Authorâ€™s reply. <i>Europace</i> , 2021, 23, 1149-1150.	1.7	1
22	Use of healthcare claims to validate the Prevention of Arrhythmia Device Infection Trial cardiac implantable electronic device infection risk score. <i>Europace</i> , 2021, 23, 1446-1455.	1.7	23
23	Device infections related to cardiac resynchronization therapy in clinical practiceâ€”An analysis of its prevalence, risk factors and routine surveillance at a single center university hospital. <i>Clinical Cardiology</i> , 2021, 44, 739-747.	1.8	1
24	Atrial fibrillation burden, episode duration and frequency in relation to quality of life in patients with implantable cardiac monitor. <i>IJC Heart and Vasculature</i> , 2021, 34, 100791.	1.1	5
25	Prevention of cardiac implantable electronic device infections: guidelines and conventional prophylaxis. <i>Europace</i> , 2021, 23, iv11-iv19.	1.7	17
26	The results of healthâ€”related quality of life assessment depend on the prevailing rhythm at the assessment: Experience from the CAPTAF trial (Catheter Ablation Compared with Pharmacological) <i>Tj ETQq0 0 0 rgB7 /Overlækk 10 Tf 50</i>	1.7	17
27	QRS dispersion detected in ARVC patients and healthy gene carriers using 252â€”leads body surface mapping: an explorative study of a potential diagnostic tool for arrhythmogenic right ventricular cardiomyopathy. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2021, 44, 1355-1364.	1.2	6
28	OUP accepted manuscript. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, , .	3.0	1
29	In-hospital and 12-month follow-up outcome from the ESC-EORP EHRA Atrial Fibrillation Ablation Long-Term registry: sex differences. <i>Europace</i> , 2020, 22, 66-73.	1.7	33
30	European Heart Rhythm Association (EHRA) international consensus document on how to prevent, diagnose, and treat cardiac implantable electronic device infectionsâ€”endorsed by the Heart Rhythm Society (HRS), the Asia Pacific Heart Rhythm Society (APHRS), the Latin American Heart Rhythm Society (LAHRS), International Society for Cardiovascular Infectious Diseases (ISCVID) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) in collaboration with the European	1.7	216
31	diagnose, and treat cardiac implantable electronic device infectionsâ€”endorsed by the Heart Rhythm Society (HRS), the Asia Pacific Heart Rhythm Society (APHRS), the Latin American Heart Rhythm Society (LAHRS), International Society for Cardiovascular Infectious Diseases (ISCVID) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) in collaboration with the European	1.4	111
32	Which patients with atrial fibrillation undergo an ablation procedure today in Europe? A report from the ESC-EHRA-EORP Atrial Fibrillation Ablation Long-Term and Atrial Fibrillation General Pilot Registries. <i>Europace</i> , 2020, 22, 250-258.	1.7	7
33	The effect of centre volume and procedure location on major complications and mortality from transvenous lead extraction: an ESC EHRA EORP European Lead Extraction ConTRolled ELECTRa registry subanalysis. <i>Europace</i> , 2020, 22, 1718-1728.	1.7	22
34	Atrial fibrillation ablation long-term ESC-EHRA EORP AFA LT registry: in-hospital and 1-year follow-up findings in Italy. <i>Journal of Cardiovascular Medicine</i> , 2020, 21, 740-748.	1.5	3
35	Efficacy and safety of dronedarone by atrial fibrillation history duration: Insights from the <sc>ATHENA</sc> study. <i>Clinical Cardiology</i> , 2020, 43, 1469-1477.	1.8	8
36	Effects of COVID-19 lockdown strategies on management of atrial fibrillation. <i>European Heart Journal</i> , 2020, 41, 3080-3082.	2.2	4

#	ARTICLE	IF	CITATIONS
55	Cardiac resynchronization therapy pacemaker or cardiac resynchronization therapy defibrillator: what determines the choice? Findings from the ESC CRT Survey II. <i>Europace</i> , 2019, 21, 918-927.	1.7	19
56	Major cardiac and vascular complications after transvenous lead extraction: acute outcome and predictive factors from the ESC-EHRA ELECTRa (European Lead Extraction ConTRolled) registry. <i>Europace</i> , 2019, 21, 771-780.	1.7	56
57	Atrial fibrillation history impact on catheter ablation outcome. Findings from the ESC-EHRA Atrial Fibrillation Ablation Long-Term Registry. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2019, 42, 313-320.	1.2	9
58	Clinical outcome of the 2nd generation cryoballoon for pulmonary vein isolation in patients with persistent atrial fibrillation – A sub-study of the randomized trial evaluating single versus dual cryoballoon applications. <i>International Journal of Cardiology</i> , 2019, 278, 120-125.	1.7	6
59	Cryoballoon vs. radiofrequency ablation for atrial fibrillation: a study of outcome and safety based on the ESC-EHRA atrial fibrillation ablation long-term registry and the Swedish catheter ablation registry. <i>Europace</i> , 2019, 21, 581-589.	1.7	69
60	Impact of body mass index on the outcome of catheter ablation of atrial fibrillation. <i>Heart</i> , 2019, 105, 244-250.	2.9	67
61	European Heart Rhythm Association (EHRA) consensus document on the management of supraventricular arrhythmias, endorsed by Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLAECE). <i>European Heart Journal</i> , 2018, 39, ehw455.	2.2	28
62	CRT Survey II: a European Society of Cardiology survey of cardiac resynchronisation therapy in 11 088 patients – who is doing what to whom and how?. <i>European Journal of Heart Failure</i> , 2018, 20, 1039-1051.	7.1	107
63	Acute and long-term efficacy and safety with a single cryoballoon application as compared with the standard dual application strategy: a prospective randomized study using the second-generation cryoballoon for pulmonary vein isolation in patients with symptomatic atrial fibrillation. <i>Europace</i> , 2018, 20, 1598-1605.	1.7	18
64	Integrating new approaches to atrial fibrillation management: the 6th AFNET/EHRA Consensus Conference. <i>Europace</i> , 2018, 20, 395-407.	1.7	95
65	2018 EHRA expert consensus statement on lead extraction: recommendations on definitions, endpoints, research trial design, and data collection requirements for clinical scientific studies and registries: endorsed by APHRS/HRS/LAHRs. <i>Europace</i> , 2018, 20, 1217-1217.	1.7	243
66	European Heart Rhythm Association (EHRA) position paper on arrhythmia management and device therapies in endocrine disorders, endorsed by Asia Pacific Heart Rhythm Society (APHRS) and Latin American Heart Rhythm Society (LAHRs). <i>Europace</i> , 2018, 20, 895-896.	1.7	24
67	Quality of life is not improved after mitral valve surgery combined with epicardial left atrial cryoablation as compared with mitral valve surgery alone: a substudy of the double blind randomized SWEDish Multicentre Atrial Fibrillation study (SWEDMAF). <i>Europace</i> , 2018, 20, f343-f350.	1.7	12
68	CABANA Trial, another favourable view. <i>European Heart Journal</i> , 2018, 39, 2771-2772.	2.2	1
69	Percutaneous left atrial appendage occlusion: the Munich consensus document on definitions, endpoints, and data collection requirements for clinical studies. <i>Europace</i> , 2017, 19, euw141.	1.7	120
70	Contemporary management of patients undergoing atrial fibrillation ablation: in-hospital and 1-year follow-up findings from the ESC-EHRA atrial fibrillation ablation long-term registry. <i>European Heart Journal</i> , 2017, 38, ehw564.	2.2	151
71	Sex-related differences in atrial fibrillation: can we discern true disparities from biases?. <i>Heart</i> , 2017, 103, 979-981.	2.9	6
72	The European Lead Extraction ConTRolled (ELECTRa) study: a European Heart Rhythm Association (EHRA) Registry of Transvenous Lead Extraction Outcomes. <i>European Heart Journal</i> , 2017, 38, 2995-3005.	2.2	339

#	ARTICLE	IF	CITATIONS
73	Viewpoint: Stroke Prevention in Recent Guidelines for the Management of Patients with Atrial Fibrillation: An Appraisal. <i>American Journal of Medicine</i> , 2017, 130, 773-779.	1.5	6
74	Decision-Making in Clinical Practice: Oral Anticoagulant Therapy in Patients with Non-valvular Atrial Fibrillation and a Single Additional Stroke Risk Factor. <i>Advances in Therapy</i> , 2017, 34, 357-377.	2.9	14
75	Persistency of left atrial linear lesions after radiofrequency catheter ablation for atrial fibrillation: Data from an invasive follow-up electrophysiology study. <i>Journal of Cardiovascular Electrophysiology</i> , 2017, 28, 1403-1414.	1.7	13
76	Left atrial function after epicardial pulmonary vein isolation in patients with atrial fibrillation. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2017, 50, 195-201.	1.3	4
77	European Heart Rhythm Association (EHRA) consensus document on the management of supraventricular arrhythmias, endorsed by Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLAECE). <i>Europace</i> , 2017, 19, 465-511.	1.7	118
78	Assessment of Use vs Discontinuation of Oral Anticoagulation After Pulmonary Vein Isolation in Patients With Atrial Fibrillation. <i>JAMA Cardiology</i> , 2017, 2, 146.	6.1	54
79	Supraventricular Arrhythmias in Patients with Adult Congenital Heart Disease. <i>Arrhythmia and Electrophysiology Review</i> , 2017, 6, 42.	2.4	11
80	Executive Summary: European Heart Rhythm Association Consensus Document on the Management of Supraventricular Arrhythmias. <i>Arrhythmia and Electrophysiology Review</i> , 2016, 5, 210.	2.4	4
81	Perioperative management of antithrombotic treatment during implantation or revision of cardiac implantable electronic devices: the European Snapshot Survey on Procedural Routines for Electronic Device Implantation (ESS-PREDI). <i>Europace</i> , 2016, 18, 778-784.	1.7	19
82	Effect of parasympathetic nerve stimulation on atrial and atrioventricular nodal electrophysiological characteristics. <i>International Journal of Cardiology</i> , 2016, 205, 83-85.	1.7	5
83	Differences in attitude, education, and knowledge about oral anticoagulation therapy among patients with atrial fibrillation in Europe: result of a self-assessment patient survey conducted by the European Heart Rhythm Association. <i>Europace</i> , 2016, 18, 463-467.	1.7	49
84	Programmed ventricular stimulation early after myocardial infarction: authors' reply. <i>Europace</i> , 2016, 18, 789.2-790.	1.7	0
85	Thoracoscopic epicardial left atrial ablation in symptomatic patients with atrial fibrillation. <i>Europace</i> , 2016, 18, 1538-1544.	1.7	19
86	A roadmap to improve the quality of atrial fibrillation management: proceedings from the fifth Atrial Fibrillation Network/European Heart Rhythm Association consensus conference. <i>Europace</i> , 2016, 18, 37-50.	1.7	121
87	Patients' attitude and knowledge about oral anticoagulation therapy: results of a self-assessment survey in patients with atrial fibrillation conducted by the European Heart Rhythm Association. <i>Europace</i> , 2016, 18, 151-155.	1.7	50
88	Management of paediatric arrhythmias in Europe: authors' reply. <i>Europace</i> , 2015, 17, 1879.2-1880.	1.7	0
89	Clinical management of arrhythmias in elderly patients: results of the European Heart Rhythm Association survey. <i>Europace</i> , 2015, 17, 314-317.	1.7	30
90	Use of fluoroscopy in clinical electrophysiology in Europe: results of the European Heart Rhythm Association Survey. <i>Europace</i> , 2015, 17, 1149-1152.	1.7	32

#	ARTICLE	IF	CITATIONS
91	Current ablation techniques for persistent atrial fibrillation: results of the European Heart Rhythm Association Survey. <i>Europace</i> , 2015, 17, 1596-1600.	1.7	46
92	EHRA research network surveys: 6 years of EP wires activity. <i>Europace</i> , 2015, 17, 1733-1738.	1.7	0
93	European Cardiac Resynchronization Therapy Survey II: rationale and design. <i>Europace</i> , 2015, 17, 137-141.	1.7	22
94	How are patients with atrial fibrillation approached and informed about their risk profile and available therapies in Europe? Results of the European Heart Rhythm Association Survey. <i>Europace</i> , 2015, 17, 468-472.	1.7	27
95	Do cardiologists follow the European guidelines for cardiac pacing and resynchronization therapy? Results of the European Heart Rhythm Association survey. <i>Europace</i> , 2015, 17, 148-151.	1.7	10
96	Increase of Ventricular Interval During Atrial Fibrillation by Atrioventricular Node Vagal Stimulation. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2015, 8, 562-568.	4.8	3
97	2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. <i>Europace</i> , 2015, 17, euv319.	1.7	635
98	Catheter ablation for atrial fibrillation: results from the first European Snapshot Survey on Procedural Routines for Atrial Fibrillation Ablation (ESS-PRAFA) Part II. <i>Europace</i> , 2015, 17, 1727-1732.	1.7	36
99	Management of patients with ventricular tachycardia in Europe: results of the European Heart Rhythm Association survey. <i>Europace</i> , 2015, 17, 1294-1299.	1.7	9
100	How are arrhythmias detected by implanted cardiac devices managed in Europe? Results of the European Heart Rhythm Association Survey. <i>Europace</i> , 2015, 17, 1449-1453.	1.7	6
101	Intra-operative defibrillation testing and clinical shock efficacy in patients with implantable cardioverter-defibrillators: the NORDIC ICD randomized clinical trial. <i>European Heart Journal</i> , 2015, 36, 2500-2507.	2.2	98
102	Personnel, equipment, and facilities for electrophysiological and catheter ablation procedures in Europe: results of the European Heart Rhythm Association Survey. <i>Europace</i> , 2014, 16, 1078-1082.	1.7	7
103	Management of malfunctioning and recalled pacemaker and defibrillator leads: results of the European Heart Rhythm Association survey. <i>Europace</i> , 2014, 16, 1674-1678.	1.7	32
104	How are arrhythmias managed in the paediatric population in Europe? Results of the European Heart Rhythm survey. <i>Europace</i> , 2014, 16, 1852-1856.	1.7	24
105	Work-up and management of lone atrial fibrillation: results of the European Heart Rhythm Association Survey. <i>Europace</i> , 2014, 16, 1521-1523.	1.7	12
106	Standards for device implantation and follow-up: personnel, equipment, and facilities: results of the European Heart Rhythm Association Survey. <i>Europace</i> , 2014, 16, 1236-1239.	1.7	11
107	Use of event recorders and loop recorders in clinical practice: results of the European Heart Rhythm Association Survey. <i>Europace</i> , 2014, 16, 1384-1386.	1.7	28
108	Current implantable cardioverter-defibrillator programming in Europe: the results of the European Heart Rhythm Association survey. <i>Europace</i> , 2014, 16, 935-938.	1.7	10

#	ARTICLE	IF	CITATIONS
109	EHRA(European Heart Rhythm Association) EP-Wires Surveys: What Is Common Practice In Device Management?. Journal of Atrial Fibrillation, 2014, 7, 1115.	0.5	0
110	The use of imaging for electrophysiological and devices procedures: a report from the first European Heart Rhythm Association Policy Conference, jointly organized with the European Association of Cardiovascular Imaging (EACVI), the Council of Cardiovascular Imaging and the European Society of Cardiac Radiology. Europace, 2013, 15, 927-936.	1.7	38
111	Safety and efficacy of pharmacological cardioversion of atrial fibrillation using intravenous vernakalant, a new antiarrhythmic drug with atrial selectivity. Expert Opinion on Drug Safety, 2012, 11, 671-679.	2.4	7
112	What are the costs of atrial fibrillation?. Europace, 2011, 13, ii9-ii12.	1.7	29
113	Guidelines for the management of atrial fibrillation. Europace, 2010, 12, 1360-1420.	1.7	1,360
114	Drug treatment of supraventricular tachycardia. Heart, 2009, 95, 1803-1807.	2.9	2
115	A randomized double-blind study of epicardial left atrial cryoablation for permanent atrial fibrillation in patients undergoing mitral valve surgery: the SWEDish Multicentre Atrial Fibrillation study (SWEDMAF). European Heart Journal, 2007, 28, 2902-2908.	2.2	136